Actilyse50 mg/vial

Actilyse is a recombinant tissue plasminogen activator (tPA) indicated for the emergency treatment of specific thromboembolic conditions. It must only be administered in a hospital setting by clinicians experienced in thrombolytic therapy.

FDA-Approved Indications

• Acute Ischemic Stroke (AIS): For the management of acute ischemic stroke in adults, administered within a strict time window from onset of stroke symptoms (within 3 hours per original approval; guideline bodies such as the American Heart Association/American Stroke Association support use up to 4.5 hours in appropriately selected patients). Imaging-confirmed absence of hemorrhage and exclusion of contraindications is mandatory before Actilyse is given.
• Acute Myocardial Infarction (AMI): For the lysis of thrombi obstructing coronary arteries in adults with acute MI, to reduce infarct size and reduce the incidence of heart failure and mortality.
• Acute Massive Pulmonary Embolism (PE): For the management of acute massive PE in adults, particularly when hemodynamically unstable.
• Restoration of Central Venous Access Device (CVAD) Function: For adult and pediatric patients with a CVAD (e.g., a central line) that is not functioning properly due to occlusion by a clot.

Guideline-Supported / Adjunct Use

• Extended time-window use (3-4.5 hours) of Actilyse in acute ischemic stroke is supported by AHA/ASA stroke guidelines in carefully selected patients, though this falls outside the original, narrower FDA-approved window.

Actilyse is a time-critical, specialist-administered emergency medicine and is not intended for outpatient, elective, or self-administered use.

Each vial of Alteplase contains recombinant tissue plasminogen activator as a sterile, lyophilized (freeze-dried) powder for reconstitution, commonly supplied in strengths such as 50 mg and 100 mg per vial. The powder also contains excipients such as L-arginine, phosphoric acid, and polysorbate 80. Alteplase contains no preservative and must be reconstituted only with Sterile Water for Injection, USP (without preservative), to a final concentration of 1 mg/mL before use.

Actilyse is a recombinant form of human tissue plasminogen activator (tPA), a naturally occurring serine protease enzyme produced by vascular endothelial cells that plays a central role in the breakdown of blood clots (fibrinolysis). It is manufactured using recombinant DNA technology in mammalian cell culture. As a thrombolytic ("clot-busting") agent, Actilyse is used in emergency medicine to rapidly dissolve life-threatening blood clots in specific vascular territories, restoring blood flow before irreversible tissue damage occurs.

Actilyse belongs to the therapeutic class of thrombolytic agents (fibrinolytics), specifically the tissue plasminogen activator (tPA) subclass.

Alteplase is an enzyme (serine protease) that catalyzes the conversion of plasminogen to plasmin, the enzyme responsible for breaking down fibrin, the structural protein of blood clots.

Mechanism

Compared with older, non-selective thrombolytics, Alteplase exhibits relative fibrin selectivity: it preferentially activates plasminogen bound to fibrin within a clot, which in principle limits systemic depletion of circulating fibrinogen, although clinically significant systemic fibrinolysis and bleeding risk still occur, especially at higher doses.

Pharmacokinetics

• Onset: Rapid; fibrinolysis begins within minutes of intravenous administration of Alteplase.
• Half-life: Very short, with an initial plasma half-life of approximately 4-6 minutes; most is cleared from plasma within 20 minutes, which is why Alteplase is given as an initial bolus followed by a continuous infusion for most indications.
• Metabolism/Clearance: Alteplase is predominantly cleared by the liver.

Actilyse is for intravenous use only and must be administered exclusively in a hospital setting equipped for continuous cardiac and neurological monitoring and for management of bleeding complications.

• Reconstitute Actilyse only as directed (see Reconstitution) immediately before use.
• Administer via a dedicated intravenous line where possible; avoid intramuscular injections and unnecessary arterial/venous punctures during and shortly after treatment.
• For catheter clearance, instill the dose into the occluded lumen and allow it to dwell (commonly up to 30-120 minutes, per institutional protocol) before attempting to aspirate the clot and restore patency; do not infuse this catheter-clearance dose systemically.
• Monitor vital signs, neurological status (in stroke), and puncture/access sites closely throughout and after administration for signs of bleeding.

Concomitant use of the following agents with Actilyse requires caution due to well-established, clinically significant interactions:

• Anticoagulants (e.g., heparin, warfarin, direct oral anticoagulants): Concurrent or recent use significantly increases the risk of serious bleeding, including intracranial hemorrhage, when combined with Actilyse; anticoagulant status (e.g., INR, aPTT) must be checked before giving Actilyse for stroke.
• Antiplatelet agents (e.g., aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitors): Additive bleeding risk when combined with Actilyse.
• ACE inhibitors: Increased risk of orolingual angioedema when used concurrently with Actilyse, particularly in stroke patients; monitor closely for airway compromise.
• Nitroglycerin (intravenous): May reduce the thrombolytic effect of Actilyse by increasing its hepatic clearance; use concurrent nitroglycerin infusion cautiously.

The most common and most serious adverse reaction associated with Actilyse is bleeding.

Common

• Superficial or internal bleeding (e.g., at puncture/access sites, gastrointestinal, genitourinary)
• Bruising (ecchymosis)
• Hypotension
• Nausea and vomiting

Serious (require immediate medical attention)

• Intracranial hemorrhage (the most serious complication, especially in stroke treatment)
• Orolingual angioedema (more frequent with concurrent ACE inhibitor use)
• Reperfusion arrhythmias (during treatment of myocardial infarction)
• Cholesterol embolization (rare)
• Anaphylactoid/hypersensitivity reactions (rare)

Actilyse has not been well studied in pregnant or breastfeeding women, and controlled human data are limited. Because a life-threatening emergency typically drives the decision to use Actilyse, it should be used in pregnancy only if the potential benefit to the mother is judged by the treating physician to justify the potential risk to the fetus, and only in a hospital setting with specialist input. It is not known whether Actilyse passes into human breast milk; given its very short plasma half-life and use only in acute emergencies, a physician should advise on breastfeeding timing after treatment. This decision should always involve the treating physician rather than being made independently.

Actilyse carries a major risk of bleeding, including life-threatening intracranial hemorrhage, and must be used only by clinicians experienced in thrombolytic therapy and acute stroke/MI/PE management, in a facility with immediate access to monitoring and management of bleeding complications.

• Careful patient selection against strict inclusion/exclusion criteria is essential, particularly for the stroke indication, where treatment timing and imaging-confirmed absence of hemorrhage are critical.
• Orolingual angioedema has been reported with Actilyse, particularly in patients on concurrent ACE inhibitors; monitor the airway closely during and after infusion.
• Reperfusion arrhythmias can occur during treatment of myocardial infarction; continuous cardiac monitoring is required.
• Strict timing relative to symptom onset is critical to both efficacy and safety, particularly for stroke, where the benefit-risk ratio changes significantly with time from onset.
• Avoid concurrent arterial punctures, intramuscular injections, and non-compressible vascular access during and shortly after treatment with Actilyse.
• Actilyse is a time-critical, specialist-administered emergency medication, not an outpatient or elective-use drug, and must never be self-administered.

See Contraindications for absolute exclusions and Interaction for medicines that increase these risks.

Overdose of Actilyse principally manifests as bleeding, which may be severe or life-threatening. There is no specific antidote. Any suspected overdose or significant bleeding during or after Actilyse treatment is a medical emergency: the infusion must be stopped immediately and the patient should receive urgent medical attention in a hospital setting, including supportive care (e.g., fluid/blood product replacement such as cryoprecipitate or fresh frozen plasma) and, if advised by the treating specialist, antifibrinolytic therapy. Patients, families, or caregivers should never attempt home management and should contact emergency services or a poison control center immediately if overdose or serious bleeding is suspected.

Store unreconstituted Actilyse vials at controlled room temperature (below 30°C) or under refrigeration as directed on the product packaging, protected from excessive light. Once reconstituted, use within the time specified by the manufacturer (typically within 8 hours) and do not freeze the reconstituted solution. Keep out of reach of children. Because Actilyse is administered exclusively by healthcare professionals in a hospital setting, storage is managed by the treating facility rather than the patient.

Renal Impairment

No dedicated dose adjustment for Actilyse is established in renal impairment; it should be used with the same caution and monitoring as in patients with normal renal function, per treating physician judgment.

Hepatic Impairment

Patients with severe hepatic disease are at increased risk of bleeding on Actilyse due to reduced synthesis of clotting factors and should be evaluated carefully before treatment; severe hepatic impairment with associated bleeding risk may warrant avoiding use.

Elderly

Elderly patients, particularly those over 75 years, may have a higher risk of intracranial hemorrhage with Actilyse, especially for the stroke indication; treatment decisions should carefully weigh this increased risk against the potential benefit on a case-by-case basis.

Pediatric

See Pediatric Uses.

Actilyse is administered as a single, short-course emergency treatment episode rather than an ongoing therapy. Infusion duration depends on indication: approximately 60 minutes total for acute ischemic stroke, 90 minutes to 3 hours for acute myocardial infarction depending on the regimen used, and 2 hours for acute massive pulmonary embolism. For catheter clearance, the dose is instilled and allowed to dwell for a period (commonly up to 30-120 minutes per institutional protocol) before an attempt is made to restore catheter function; it is not repeated in immediate succession without physician reassessment.

Actilyse is supplied as a sterile, lyophilized powder that must be reconstituted immediately before use. Reconstitute only with Sterile Water for Injection, USP (without preservative), directing the diluent stream into the powder, to achieve a final concentration of 1 mg/mL. Gently swirl (do not shake vigorously) to avoid excessive foaming, and allow any foam to settle before withdrawing the dose. Do not use bacteriostatic water or add other medications to the vial or infusion line. If needed, the reconstituted 1 mg/mL solution of Actilyse may be further diluted with an equal volume of sterile 0.9% Sodium Chloride Injection to 0.5 mg/mL. Use the reconstituted solution promptly and discard any unused portion per institutional protocol.

Thrombolytic agent; Fibrinolytic; Tissue plasminogen activator (tPA); Serine protease enzyme (recombinant biologic).

Alteplase works by binding to fibrin within a blood clot and converting entrapped plasminogen to plasmin. Plasmin then degrades the fibrin meshwork that gives the clot its structure, dissolving the clot and restoring blood flow through the previously obstructed vessel or catheter. Alteplase shows relative selectivity for fibrin-bound plasminogen over free circulating plasminogen, intended to concentrate its thrombolytic action at the site of the clot, although clinically significant effects on systemic coagulation still occur.

C

Safety and efficacy of Actilyse for acute ischemic stroke, myocardial infarction, and pulmonary embolism have not been established in pediatric patients, and it is not approved for these indications in children.

For restoration of function to an occluded central venous access device, Actilyse (as the low-dose catheter-clearance formulation) is approved for use in pediatric patients, dosed by weight: children weighing 30 kg or more receive 2 mg in 2 mL instilled into the catheter lumen, while children weighing less than 30 kg receive 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL. This use of Actilyse must always be supervised by a pediatric specialist in a hospital setting.